Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

1CVR

Crystal structure of the Arg specific cysteine proteinase gingipain R (RGPB)

Summary for 1CVR
Entry DOI10.2210/pdb1cvr/pdb
Related PRD IDPRD_001160
DescriptorGINGIPAIN R, D-phenylalanyl-N-[(3S)-6-carbamimidamido-1-chloro-2-oxohexan-3-yl]-L-phenylalaninamide, CALCIUM ION, ... (5 entities in total)
Functional Keywordscaspases, cysteine proteinase, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourcePorphyromonas gingivalis
Total number of polymer chains1
Total formula weight48805.14
Authors
Eichinger, A.,Beisel, H.-G. (deposition date: 1999-08-24, release date: 2000-03-01, Last modification date: 2024-10-16)
Primary citationEichinger, A.,Beisel, H.G.,Jacob, U.,Huber, R.,Medrano, F.J.,Banbula, A.,Potempa, J.,Travis, J.,Bode, W.
Crystal structure of gingipain R: an Arg-specific bacterial cysteine proteinase with a caspase-like fold.
EMBO J., 18:5453-5462, 1999
Cited by
PubMed Abstract: Gingipains are cysteine proteinases acting as key virulence factors of the bacterium Porphyromonas gingivalis, the major pathogen in periodontal disease. The 1.5 and 2.0 A crystal structures of free and D-Phe-Phe-Arg-chloromethylketone-inhibited gingipain R reveal a 435-residue, single-polypeptide chain organized into a catalytic and an immunoglobulin-like domain. The catalytic domain is subdivided into two subdomains comprising four- and six-stranded beta-sheets sandwiched by alpha-helices. Each subdomain bears topological similarities to the p20-p10 heterodimer of caspase-1. The second subdomain harbours the Cys-His catalytic diad and a nearby Glu arranged around the S1 specificity pocket, which carries an Asp residue to enforce preference for Arg-P1 residues. This gingipain R structure is an excellent template for the rational design of drugs with a potential to cure and prevent periodontitis. Here we show the binding mode of an arginine-containing inhibitor in the active-site, thus identifying major interaction sites defining a suitable pharmacophor.
PubMed: 10523290
DOI: 10.1093/emboj/18.20.5453
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon